- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BENEVOLENTAI Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 3,720 | 0,00 % | Why Recursion Pharmaceuticals Inc (RXRX) Expanded Citeline Partnership | ||
| ABCELLERA BIOLOGICS | 3,490 | 0,00 % | Truist reiterates Buy on AbCellera stock ahead of 2H26 data | ||
| ANAVEX LIFE SCIENCES | 3,075 | -0,45 % | ANAVEX LIFE SCIENCES CORP: Struktur vor Bewegung | ||
| VERACYTE | 28,280 | -1,87 % | Veracyte, Inc.: Veracyte to Participate in Upcoming Investor Conferences | Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences.
Wolfe Research Healthcare Conference New York... ► Artikel lesen | |
| ASCLETIS PHARMA | 2,040 | +3,03 % | Ascletis Pharma Inc.: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development | -Fixed-dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective... ► Artikel lesen | |
| ABSCI | 3,690 | 0,00 % | Speicher und Bürgerenergie prägen ABSI-Jahrestagung in Neuötting | Auf der 33. Jahrestagung der Arbeitsgemeinschaft Bayerischer Solarinitiativen (ABSI) diskutierten rund 240 Fachleute über die zukünftige Rolle von Stromspeichern und Bürgerenergie. Im Zentrum stand... ► Artikel lesen | |
| BIOMEA FUSION | 1,840 | 0,00 % | Biomea Fusion, Inc.: Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies | COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapyTopline... ► Artikel lesen | |
| JASPER THERAPEUTICS | 0,966 | 0,00 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update | REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody... ► Artikel lesen | |
| LANTERN PHARMA | 2,680 | 0,00 % | Lantern Pharma plant FDA-Treffen zur Anpassung seiner Lungenkrebsstudie | ||
| DAY ONE BIOPHARMACEUTICALS | 21,530 | +0,21 % | Day One Biopharmaceuticals, Inc. - 10-K/A, Annual Report | ||
| INHIBRX BIOSCIENCES | 115,09 | 0,00 % | Morning Market Movers: Axe Compute, Inhibrx Biosciences, Huachen AI Parking Management Technology, 1-800-FLOWERS.COM See Big Swings | OTTAWA (dpa-AFX) - At 9:00 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 337,29 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| IMMUNOVANT | 29,490 | 0,00 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| MAZE THERAPEUTICS | 26,500 | +3,27 % | Maze Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 21,640 | 0,00 % | Erasca, Inc. - 8-K, Current Report |
BENEVOLENTAI gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BENEVOLENTAI finden Sie auf Wallstreet Online.